EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comparison between [68Ga]Ga-PSMA-617 and [18F]FET PET as Imaging Biomarkers in Adult Recurrent Glioblastoma

Caterina Brighi iD, Simon Puttick, Amanda Woods, Paul Keall, Paul A Tooney iD, David E J Waddington, Vicki Sproule, Stephen Rose, Michael Fay

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms242216208 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Caterina Brighi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Image X Institute, Faculty of Medicine and Health, Sydney School of Health Sciences, The University of Sydney, Sydney 2015, Australia. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Prostatic Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Rotary Club of Rockhampton North, GenesisCare Newcastle, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this prospective clinical study was to evaluate the potential of the prostate specific membrane antigen (PSMA) targeting ligand, [68Ga]-PSMA–Glu–NH–CO–NH–Lys-2-naphthyl-L-Ala-cyclohexane-DOTA ([68Ga]Ga-PSMA-617) as a positron emission tomography (PET) imaging biomarker in recurrent glioblastoma patients. Patients underwent [68Ga]Ga-PSMA-617 and O-(2-[18F]-fluoroethyl)-L-tyrosine ([18F]FET) PET scans on two separate days. [68Ga]Ga-PSMA-617 tumour selectivity was assessed by comparing tumour volume delineation and by assessing the intra-patient correlation between tumour uptake on [68Ga]Ga-PSMA-617 and [18F]FET PET images. [68Ga]Ga-PSMA-617 tumour specificity was evaluated by comparing its tumour-to-brain ratio (TBR) with [18F]FET TBR and its tumour volume with the magnetic resonance imaging (MRI) contrast-enhancing (CE) tumour volume. Ten patients were recruited in this study. [68Ga]Ga-PSMA-617-avid tumour volume was larger than the [18F]FET tumour volume (p = 0.063). There was a positive intra-patient correlation (median Pearson r = 0.51; p < 0.0001) between [68Ga]Ga-PSMA-617 and [18F]FET in the tumour volume. [68Ga]Ga-PSMA-617 had significantly higher TBR (p = 0.002) than [18F]FET. The [68Ga]Ga-PSMA-617-avid tumour volume was larger than the CE tumour volume (p = 0.0039). Overall, accumulation of [68Ga]-Ga-PSMA-617 beyond [18F]FET-avid tumour regions suggests the presence of neoangiogenesis in tumour regions that are not overly metabolically active yet. Higher tumour specificity suggests that [68Ga]-Ga-PSMA-617 could be a better imaging biomarker for recurrent tumour delineation and secondary treatment planning than [18F]FET and CE MRI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsProstatic NeoplasmsMaleHumansAdultGallium RadioisotopesProspective StudiesPositron-Emission TomographyContrast MediaMagnetic Resonance ImagingChronic DiseaseDipeptidesHeterocyclic Compounds, 1-RingProstate-Specific Antigen

Stichwörter der Autor:innen

[68Ga]Ga-PSMA-617positron emission tomography imaging of glioblastomarecurrent glioblastomatheranostics for glioblastoma

Substanzen

Gallium RadioisotopesContrast MediaPSMA-617DipeptidesHeterocyclic Compounds, 1-RingProstate-Specific Antigen

Autor:innen und Institutionen

  • Image X Institute, Faculty of Medicine and Health, Sydney School of Health Sciences, The University of Sydney, Sydney 2015, Australia.
  • AdvanCell Isotopes Pty Ltd., Sydney 2000, Australia.
  • GenesisCare, Newcastle 2290, Australia.
  • MHF Centre for Brain Cancer Research, College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle 2308, Australia.

ORCID-Profile: Caterina Brighi, Paul A Tooney

Förderung

  • The Rotary Club of Rockhampton North
  • GenesisCare Newcastle
  • National Health and Medical Research Council
  • MHF Centre for Brain Cancer Research at the University of Newcastle
  • CSIRO Probing Biosystems Future Science Platform
  • Cancer Institute of New South Wales
  • Cancer Institute NSW

Zitieren

APA

Brighi, C., Puttick, S., Woods, A., Keall, P., Tooney, P. A., Waddington, D. E. J., Sproule, V., Rose, S., & Fay, M. (2023). Comparison between [68Ga]Ga-PSMA-617 and [18F]FET PET as Imaging Biomarkers in Adult Recurrent Glioblastoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242216208

Vancouver

Brighi C, Puttick S, Woods A, Keall P, Tooney PA, Waddington DEJ, et al. Comparison between [68Ga]Ga-PSMA-617 and [18F]FET PET as Imaging Biomarkers in Adult Recurrent Glioblastoma. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242216208

BibTeX
@article{Brighi2023,
  author = {Brighi, Caterina and Puttick, Simon and Woods, Amanda and Keall, Paul and Tooney, Paul A and Waddington, David E J and Sproule, Vicki and Rose, Stephen and Fay, Michael},
  title = {Comparison between [68Ga]Ga-PSMA-617 and [18F]FET PET as Imaging Biomarkers in Adult Recurrent Glioblastoma},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms242216208}
}
Kostenlos starten →